1. Department of Medicine Task Force on Research

2. Committee Charge  Develop a unifying vision to become leaders in translational research Achieve top 10 status nationally  Develop common strategies for success across Divisions Training of future physician-scientists Recruiting and supporting translational scientists Building the infrastructure for the full range of translational research (i.e., T1 - T4) Increasing the number of “large” R, P, U grants (clinical, multi-investigator, etc.)

3. Where are we now ? (20) (24)

4. Strengths  Regional (and in some cases national) recognition in a broad array of clinical specialties and research areas. Auto-immunity & inflammation; the microbiome, cardiovascular disease, asthma; single-site and growing strength in multi-site clinical trials and trial coordinating.  A cadre of successful physician-investigators with robust research programs in the Department of Medicine.  Access to unique patient populations (TH, BV, VA) and healthcare systems for clinical and population-based research.  Strong philanthropic base

5. Weaknesses  Lack of integrated Departmental research vision & strategy  Lack of alignment of an Institutional research mission with our clinical and educational missions  Under-developed Departmental research infrastructure  Limited exposure of trainees to successful physician- investigators  Poor record of recruiting/retaining our own top trainees  Ad hoc nature of recruitment process Identification of candidates, startup packages, benchmarks of success

6. Threats  Very unfavorable funding environment at NIH and other governmental agencies  Changing healthcare systems may impact clinical revenue stream  Actual and perceived damage to NYU Langone Medical Center by Hurricane Sandy  Competition from other academic medical centers both locally and nationally for top talent New research buildings at Sinai, Cornell, MSK, & Columbia

7. Opportunities  Restructure our training programs to enhance the development of academic physician-investigators.  Build translational programs around strategically important patient populations that can enhance our reputation Common diseases (CV, DM, etc.) as well as niche/rare diseases.  Align Departmental recruitment with Institutional strategic priority areas Genomics, metabolomics, inflammation, stem cells & regenerative medicine, experimental therapeutics, imaging (potential examples)  Restructure our teaching hospitals and our outpatient practice sites Enhance patient-based clinical and translational research.  Expand our philanthropic base to offset declines in NIH funding.

8. Metabolic Diseases (DM, Obesity) Cardiovascular Diseases (CAD, CHF, SCD, AF) Auto Immunity, Infection and Inflammation (SLE, RA, IBD) Aging and Alzheimers (Dementia) Metabolic Diseases (DM, Obesity) Cardiovascular Diseases (CAD, CHF, SCD, AF) Auto Immunity, Infection and Inflammation (SLE, RA, IBD) Aging and Alzheimers (Dementia) Institutional Cross-Disciplinary Strategic Focus Areas and Cores (possible areas) Stem Cells & Regenerative Med Medical Genomics Medical Genomics Experimental Therapeutics Experimental Therapeutics Metabolomics Imaging Basic and T1 – T4 Translational Research Programs Basic Scientists Population/Database Department of Medicine Disease-Centered Strategy Translational Investigators

9. NIH Rankings: 2020